Anavex Life Sciences Corp (AVXL)

[sokol]

I don't think it is that simple. Solanezmab, Lily's drug for example, undergoing clinical trials is covered by patents. If
solanezumab receives marketing authorization, PDL will receive a patent royalty of three percent for product manufactured and/or sold in the United States before expiration of Queen et al. patents and a two percent know-how royalty on worldwide sales for 12.5 years from date of first commercial sale. Why would big pharma, like Lily and others, want Anavex to succeed when they are seeking FDA approval for other amyloid type drugs covered by patents?

Likewise, see the Biogen clinical trials for its drug covered by patents.